FINWIRES · TerminalLIVE
FINWIRES

Huluwa Pharma's Zoledronic Acid Concentrate for Injection Gets Registration Certificate

By

Hainan Huluwa Pharmaceutical's (SHA:605199) zoledronic acid concentrate for injection obtained a drug registration certificate from China's National Medical Products Administration, according to a Shanghai bourse filing on Saturday.

The pharmaceutical company's shares jumped 3% at the close of Monday's trade.

The drug is used in combination with standard antitumor therapy for the treatment of skeletal complications in patients with bone metastases from solid tumors and multiple myeloma.

Related Articles

Asia

Shibaura Machine's Profit Plummets 92% in Fiscal Year 2025

Shibaura Machine's (TYO:6104) profit attributable to owners of the parent plunged 92% to 1.03 billion yen for the fiscal year 2025 from 12.6 billion yen a year earlier.The machinery manufacturer's basic earnings per share declined to 43.51 yen from 529.56 yen a year ago, according to a Tokyo bourse filing on Monday.Net sales dropped 21% to 132.8 billion yen from 168.2 billion yen in the prior year.It declared a final dividend of 70 yen per share, payable from June 16.For the fiscal year 2026, the company expects attributable profit of 2 billion yen, basic EPS of 84.58 yen, and net sales/revenue of 137 billion yen.Shibaura Machine plans to pay interim and year-end dividends of 70 yen per share, each, for the year, which is the same as the amount declared in the year-ago period.

$TYO:6104
Asia

NBCC (India) Wins Two Construction Contracts; Shares Up 3%

NBCC (India) (NSE:NBCC, BOM:534309) received two work orders for construction projects from Navodaya Vidyalaya Samiti and Indian Bank (NSE:INDIANB, BOM:532814), according to a Saturday filing on Indian bourses.Shares of the company rose nearly 3% in Monday's trade.Navodaya Vidyalaya Samiti awarded NBCC a project worth 69.2 million rupees for extension work of an existing school building and additional staff quarters, the filing said.Separately, Indian Bank awarded NBCC a 356.3 million rupees contract for the construction of office premises in Andhra Pradesh.

$BOM:534309$NSE:NBCC
Asia

Tinavi Medical Technologies Allocates 83 Million Yuan for 2026 Related-Party Transactions

Tinavi Medical Technologies (SHA:688277) set aside 83 million yuan for related-party transactions for the year, according to a Saturday filing on the Shanghai bourse.The Chinese orthopedic surgical robot manufacturer's shares slipped 1% at the close of Monday's trade.In 2025, related-party transactions amounted to 26.4 million yuan.

$SHA:688277